---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-043042"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2026-06-15T13:18:44+00:00"
generated_at: "2026-06-15T13:20:10.600838+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics reports 29% ORR for CTIM-76 in Phase 1 PROC trial; FDA Fast Track granted

## Summary
- 29% confirmed overall response rate per RECIST v1.1 in heavily pretreated PROC patients (median 7 prior lines).
- Cytokine Release Syndrome limited to Grade 1 in 11% of PROC patients at active doses; supports outpatient dosing.
- PK data supports exploration of Q3W dosing in 2H 2026; Phase 1b dose expansion planned for 2027.
- CTIM-76 granted FDA Fast Track Designation for platinum-resistant ovarian cancer.

## SEC filing metadata
- accession: 0001628280-26-043042
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2026-06-15T13:18:44+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/0001628280-26-043042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/cntx-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-043042
- JSON: https://secwatch.observer/filing/0001628280-26-043042.json
- Plain text: https://secwatch.observer/filing/0001628280-26-043042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.